Kyverna Therapeutics Reports Positive Data for Stiff Person Syndrome…

Event summary

Kyverna Therapeutics to present full one-year results from KYSA-8 trial in Stiff Person Syndrome (SPS) at MSToronto2026, showing sustained clinical benefit and well-tolerated safety profile.
Updated Phase 1 investigator-initiated trial data for progressive multiple sclerosis (MS) to be presented, highlighting encouraging clinical activity and safety.
Company aims to complete Biologics License Application (BLA) submission for miv-cel in SPS this quarter.
Miv-cel is the first CAR T-cell therapy candidate for autoimmune diseases, with potential first-in-class approval for SPS.

The big picture

Kyverna Therapeutics is positioning itself at the forefront of neuroimmunology with miv-cel, a CAR T-cell therapy designed to reset the immune system in autoimmune diseases. The positive data in SPS and progressive MS could redefine treatment paradigms for rare neurologic conditions, addressing significant unmet medical needs. The company's progress in securing regulatory approvals and preparing for commercialization will be critical in determining its long-term success in this emerging therapeutic space.

What we're watching

Regulatory Milestones: Whether Kyverna can secure FDA approval for miv-cel in SPS by year-end, positioning it as the first CAR T-cell therapy for autoimmune diseases.
Commercialization Strategy: The pace at which Kyverna can prepare for the commercial launch of miv-cel, assuming regulatory approval.
Pipeline Expansion: How Kyverna will leverage positive SPS data to advance its pipeline in other neuroimmunology indications, such as generalized myasthenia gravis (gMG).